Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Coronary Occlusion, Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
clopidogrel, placebo
Drug
Lead sponsor
Accumetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
72
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more
Conditions
Stable Angina
Interventions
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

ABSORB III Randomized Controlled Trial (RCT)

NCT01751906
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
190
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 145 more
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stent Thrombosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Results available

The Medtronic RESOLUTE US Clinical Trial

NCT00726453
Conditions
Coronary Artery Disease
Interventions
Resolute Zotarolimus-Eluting Coronary Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Tyler, Texas
Active, not recruiting Not applicable Interventional Results available

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976
Conditions
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions
GORE® VIAFORT Vascular Stent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
8
States / cities
Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Conditions
Stent Thrombosis, Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Sacramento, California
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Completed Not applicable Interventional Results available

Resolute Integrity US Extended Length Sub-Study(RI US XL)

NCT01913600
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • San Jose, California • Stanford, California + 18 more
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Withdrawn Not applicable Interventional

ABSORB Post-Approval Clinical Study

NCT02943616
Conditions
Ischemic Heart Disease
Interventions
Absorb BVS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Tallahassee, Florida • Indianapolis, Indiana • Louisville, Kentucky + 2 more
Conditions
May-Thurner Syndrome, Deep Vein Thrombosis, Chronic Venous Insufficiency
Interventions
Duo Venous Stent System
Device
Lead sponsor
Vesper Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Orange, California • Palo Alto, California • Darien, Connecticut + 24 more
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Conditions
Carotid Stenosis
Interventions
Carotid Stent Implantation, Embolic Protection
Device
Lead sponsor
Kensey Nash Corporation
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Birmingham, Alabama • Fairhope, Alabama • Beverly Hills, California + 25 more
Conditions
Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions
Cipherome Lighthouse Pilot
Diagnostic Test
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Edinburg, Texas
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Conditions
Coronary Artery Disease
Interventions
COBRA PzF
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Bakersfield, California • Miami Beach, Florida • Atlanta, Georgia + 18 more
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Conditions
Bleeding, Thrombosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California